N. Wilcken

536 total citations
5 papers, 198 citations indexed

About

N. Wilcken is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, N. Wilcken has authored 5 papers receiving a total of 198 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Cancer Research and 1 paper in Molecular Biology. Recurrent topics in N. Wilcken's work include Cancer Treatment and Pharmacology (3 papers), Breast Cancer Treatment Studies (3 papers) and HER2/EGFR in Cancer Research (1 paper). N. Wilcken is often cited by papers focused on Cancer Treatment and Pharmacology (3 papers), Breast Cancer Treatment Studies (3 papers) and HER2/EGFR in Cancer Research (1 paper). N. Wilcken collaborates with scholars based in Australia, Sweden and Germany. N. Wilcken's co-authors include Elizabeth A. Musgrove, Owen W.J. Prall, R. Sutherland, A. Hamilton, Davina Ghersi, Anna K. Nowak, David Goldstein, Stephen Clarke, Oriana Nanni and Phyllis Butow and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

N. Wilcken

5 papers receiving 194 citations

Peers

N. Wilcken

ONCOL

MB

CR

GENET

PRM

Dena Jerjees United Kingdom

Valentina Scabia Switzerland

Katrien Geboers Belgium

Henry Paik United States

Shin-ichiro Horiguchi Japan

Pavana Anur United States

Patrick Jaynes Singapore

Hsiao-Ching Chuang United States

Stacey E. P. Joosten Netherlands

Fangxue Yan United States

Dena Jerjees United Kingdom

N. Wilcken

121 ×0.9

ONCOL

116 ×1.3

MB

107 ×1.3

CR

97 ×1.9

GENET

39 ×1.6

PRM

Citations per year, relative to N. Wilcken N. Wilcken (= 1×) peers Dena Jerjees

Countries citing papers authored by N. Wilcken

Since Specialization

Citations

This map shows the geographic impact of N. Wilcken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Wilcken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Wilcken more than expected).

Fields of papers citing papers by N. Wilcken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Wilcken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Wilcken. The network helps show where N. Wilcken may publish in the future.

Co-authorship network of co-authors of N. Wilcken

This figure shows the co-authorship network connecting the top 25 collaborators of N. Wilcken. A scholar is included among the top collaborators of N. Wilcken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Wilcken. N. Wilcken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Gennari, Alessandra, Maria Pia Sormani, Oriana Nanni, et al.. (2010). Impact of first-line chemotherapy duration in metastatic breast cancer: A systematic review.. Journal of Clinical Oncology. 28(15_suppl). 1023–1023. 2 indexed citations

2.

Cortés, Javier, Xavier Pivot, Andreas Schneeweiß, et al.. (2009). Safety of surgery in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) treated with docetaxel (D) plus bevacizumab (BV) or placebo (PL) in the AVADO phase III study.. Cancer Research. 69(2_Supplement). 1030–1030. 3 indexed citations

3.

Leighl, N. B., Heather L. Shepherd, Phyllis Butow, et al.. (2007). When the goal is not cure: A randomized trial of a patient decision aid in advanced colorectal cancer. Journal of Clinical Oncology. 25(18_suppl). 6509–6509. 2 indexed citations

4.

Nowak, Anna K., et al.. (2004). Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. The Lancet Oncology. 5(6). 372–380. 91 indexed citations

5.

Wilcken, N., Owen W.J. Prall, Elizabeth A. Musgrove, & R. Sutherland. (1997). Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens.. PubMed. 3(6). 849–54. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact